Unresectable advanced or recurrent gastric cancer
Conditions
Interventions
None listed
Sponsors
Osaka University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age over 20 years old. 2) Histologically diagnosed unresectable advanced or recurrent gastric or esophagogastric junction adenocarcinoma. 3) Tumor tissues for biomarker examination are available. 4) Treatment with more than 2 regimens is provided for unresectable advanced or recurrent gastric or esophagogastric cancer. 5) Nivolumab treatment is planning to go, is going, or was performed as a treatment with later than third rejimens. 6) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Synchronous or metachronous (within 5 years) double cancers, except for intraepithelial tumor (Carcinoma in situ) or intramucosal tumor curatively resectable by local therapy at the time of Nivolumab treatment. 2) History of medical therapy for the purpose of the immune checkpoint inhibitors such as antiPD-1 antibody, antiPD-L1 antibody, antiCTLA-4 antibody or other T cell regulator before the Nivolumab treatment. 3) Having severe psychological illness and difficult to make a judgement for participation in the study. 4) Judged to be unfit to participate in the study by investigater.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between overall survival (OS) and the protein expression of each factor. | — |
Countries
Japan
Contacts
Public ContactYukinori Kurokawa
Graduated School of Medicine, Osaka University Department of Gastroenterological Surgery
Outcome results
None listed